Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 8/20 | 0.50 |
| ▸ | OGA | O60502 | 1/20 | 0.41 |
| ▸ | PYGB | P11216 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.35 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.35 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.35 |
| ▸ | AMY2A | P04746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18793874 | 1.00 | LGALS8 (0.50) | LGALS8OGAPYGBL3MBTL1MAPT | |
| SCHEMBL15691431 | 1.00 | LGALS8 (0.50) | LGALS8OGAPYGBL3MBTL1MAPT | |
| SCHEMBL13005416 | 1.00 | LGALS8 (0.50) | LGALS8OGAPYGBL3MBTL1MAPT | |
| SCHEMBL16790797 | 0.83 | LGALS8 (0.49) | LGALS8OGAPYGBL3MBTL1LGALS1 | |
| SCHEMBL12360822 | 0.82 | LGALS8 (0.36) | LGALS8OGA | |
| SCHEMBL12376380 | 0.82 | LGALS8 (0.36) | LGALS8OGA | |
| SCHEMBL21562952 | 0.82 | LGALS8 (0.39) | LGALS8 | |
| SCHEMBL22096076 | 0.82 | LGALS8 (0.36) | LGALS8OGA | |
| SCHEMBL13513423 | 0.82 | LGALS8 (0.36) | LGALS8OGA | |
| SCHEMBL27393414 | 0.82 | LGALS8 (0.36) | LGALS8OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162603-A1 | COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION | IONIS PHARMACEUTICALS, INC. (US) | 2022-05-26 | — | — | US | disclosed |
| US-11078485-B2 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation | IONIS PHARMACEUTICALS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200276222-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | IONIS PHARMACEUTICALS, INC. (US) | 2020-09-03 | — | — | US | disclosed |
| US-10478449-B2 | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations | IONIS PHARMACEUTICALS, INC. (US) | 2019-11-19 | — | — | US | disclosed |
| US-10266825-B2 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation | IONIS PHARMACEUTICALS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180200282-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | IONIS PHARMACEUTICALS, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180200282-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | IONIS PHARMACEUTICALS, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180104271-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180104272-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180104271-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20080027019-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | ISIS PHARMACEUTICALS, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-7307069-B2 | Antisense oligonucleotide modulation of STAT3 expression | ISIS PHARMACEUTICALS, INC. (US) | 2007-12-11 | — | — | US | disclosed |
| US-20070276139-A1 | Substituted Pixyl Protecting Groups for Oligonucleotide Synthesis | ISIS PHARMACEUTICALS, INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070276139-A1 | Substituted Pixyl Protecting Groups for Oligonucleotide Synthesis | ISIS PHARMACEUTICALS, INC. | 2007-11-29 | — | — | US | disclosed |
| US-7235653-B2 | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein | ISIS PHARMACEUTICALS, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235653-B2 | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein | ISIS PHARMACEUTICALS, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20070135364-A1 | Compositions and methods for the modulation of the expression of b7 protein | ISIS PHARMACEUTICALS, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070054869-A1 | Antisense modulation of superoxide dismutase 1, soluble expression | BIOGEN MA INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070015722-A1 | Double stranded compositions comprising a 3'-endo modified strand for use in gene modulation | BANK OF AMERICA, N.A. | 2007-01-18 | — | — | US | disclosed |
| US-20070015722-A1 | Double stranded compositions comprising a 3'-endo modified strand for use in gene modulation | BANK OF AMERICA, N.A. | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078485-B2 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation | NSUN2, RNMT, NSUN3 | LGALS8 1661/4885OGA 829/4885PYGB 3287/4885 |
| US-20200276222-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | NSUN2, SNRPE, RBM3 | LGALS8 1231/4885OGA 189/4885PYGB 2622/4885 |
| US-20180200282-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | NSUN2, SNRPE, RBM3 | LGALS8 1231/4885OGA 189/4885PYGB 2622/4885 |
| US-20080027019-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | CD2BP2, MICA, CD74 | LGALS8 505/4885OGA 3623/4885PYGB 4806/4885 |
| US-10478449-B2 | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations | NSUN2, SNRPE, RBM3 | LGALS8 1232/4885OGA 187/4885PYGB 2628/4885 |
| US-20070135364-A1 | Compositions and methods for the modulation of the expression of b7 protein | CD2BP2, CD74, CD47 | LGALS8 633/4885OGA 3288/4885PYGB 3085/4885 |
| US-20220162603-A1 | COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION | NSUN2, RNMT, NSUN3 | LGALS8 1618/4885OGA 856/4885PYGB 3204/4885 |
| US-20070054869-A1 | Antisense modulation of superoxide dismutase 1, soluble expression | SOD1, SOD3, RNASE1 | LGALS8 1498/4885OGA 2362/4885PYGB 2133/4885 |
| US-10266825-B2 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation | NSUN2, RNMT, NSUN3 | LGALS8 1661/4885OGA 829/4885PYGB 3287/4885 |
| US-20070276139-A1 | Substituted Pixyl Protecting Groups for Oligonucleotide Synthesis | RPP30, NOP10, NR0B1 | LGALS8 4854/4885OGA 2190/4885PYGB 3045/4885 |
| US-20180104272-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | NSUN2, SNRPE, RBM3 | LGALS8 1231/4885OGA 189/4885PYGB 2622/4885 |
| US-20180104271-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | NSUN2, SNRPE, RBM3 | LGALS8 1231/4885OGA 189/4885PYGB 2622/4885 |
| US-20070015722-A1 | Double stranded compositions comprising a 3'-endo modified strand for use in gene modulation | NSUN2, NSUN3, RNMT | LGALS8 2103/4885OGA 850/4885PYGB 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.